Cue Biopharma, Inc. (CUE)
| Market Cap | 42.45M |
| Revenue (ttm) | 27.47M |
| Net Income (ttm) | -26.60M |
| Shares Out | 3.26M |
| EPS (ttm) | -8.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 639,970 |
| Open | 17.20 |
| Previous Close | 17.93 |
| Day's Range | 10.76 - 17.20 |
| 52-Week Range | 4.97 - 30.97 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 120.00 (+820.25%) |
| Earnings Date | May 13, 2026 |
About CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinic... [Read more]
Financial Performance
In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CUE stock is "Strong Buy" and the 12-month stock price target is $120.0.
News
Cue Biopharma Announces 1-for-30 Reverse Stock Split
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...
Cue Biopharma Transcript: AGM 2026
Shareholders approved all proposals, including director elections, auditor ratification, executive compensation, and a reverse stock split. No questions were submitted, and the meeting was conducted virtually with a confirmed quorum.
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim
The biopharmaceutical company is developing injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body.
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell...
Cue Biopharma Transcript: R&D Day 2026
CUE-401, a bifunctional molecule targeting TGF-β and IL-2, is advancing to phase I trials following strong preclinical efficacy and safety data. Strategic partnerships have generated significant non-dilutive funding, de-risking the pipeline and supporting ongoing R&D.
Cue Biopharma Announces CEO Transition
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., ...
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...
Cue Biopharma Announces Pricing of $10 Million Public Offering
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...
Cue Biopharma Announces Proposed Public Offering
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M ...
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs® Novel therapeutic appr...
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025 Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic A...
Cue Biopharma Transcript: Cantor Global Healthcare Conference 2025
Phase III trials for VK2735 in obesity are progressing well, with strong efficacy and tolerability seen in phase II oral studies. The company is expanding its team, advancing an amylin analog program, and focusing on both subcutaneous and oral maintenance regimens to address long-term obesity management.
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients...
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 CUE-401, a first-in-class bispeci...
Cue Biopharma Transcript: Status Update
CUE-401, a novel bispecific biologic, demonstrated robust induction and expansion of regulatory T cells, durable suppression of autoimmunity, and favorable tolerability in preclinical models. The platform’s breadth enables targeting multiple autoimmune and cancer indications, with strategic partnerships and IND-enabling studies advancing.
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments